Comparison of the expression of β-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1

Journal of Surgical Oncology

Volumn 86, Issue 3, 2004, Pages 157-163

  Ban, Ke Chen ^a,b   Singh, Harjit ^c   Krishnan, R ^c   Seow, Heng Fong ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b Guangxi Cancer Institute   (China)

^c Selayang Hospital   (Malaysia)

Author keywords

Hepatitis B virus; Immunohistochemistry; P53

Indexed keywords

AFLATOXIN B1; BETA CATENIN; GENOMIC DNA;

ADULT; AGED; ARTICLE; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALAYSIA; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AFLATOXIN B1; AGED; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CHINA; CYTOSKELETAL PROTEINS; ENVIRONMENTAL EXPOSURE; FEMALE; HEPATITIS B; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALAYSIA; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2642540145     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20051     Document Type: Article

References (34)

1. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Sem Liver Dis 1999;19:271-285.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 2000;32:225-237.
3. Hussain SA, Ferry DR, El-Gazzaz G, et al.: Hepatocellular carcinoma. Ann Oncol 2001;12:161-172.
4. Yeh FS, Yu MC, Mo CC, et al.: Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 1989;49:2506-2509.
5. Merican I, Guan R, Amarapuka D, et al.: Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15: 1356-1361.
6. Khoo ASB, Mak JW, Ng AB, et al.: Detection of aflatoxin B1-DNA adducts in liver tissue from Malaysia. Internat Med Res J 1997;1:9-11.
7. Abdullah N, Nawawi A, Othman I: Survey of fungal counts and natural occurrence of aflatoxins in Malaysian starch-based foods. Mycopathologia 1998;143:53-58.
8. Devereux TR, Anna CH, Foley JF, et al.: Mutation of β-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 1999;18:4726-4733.
9. Devereux TR, Stern MC, Flake GP, et al.: CTNNB1 mutations and β-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog 2001;31:68-73.
10. Hsu HC, Jeng YM, Mao TL, et al.: β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-770.
11. de La Coste A, Romagnolo B, Billuart P, et al.: Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851.
12. Montesano R, Hainaut P, Wild CP: Hepatocellular carcinoma: From gene to public health. J Natl Cancer Inst 1997;89:1844-1851.
13. Ng IO, Lai EC, Chan AS, et al.: Overexpression of p53 in hepatocellular carcinomas: A clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995;10:250-255.
14. Piao Z, Kim H, Jeon BK, et al.: Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997;80:865-872.
15. Honda K, Sbisa E, Tullo A, et al.: p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998;77:776-782.
16. Lim HY, Joo HJ, Choi JH, et al.: Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-525.
17. Moskaluk CA, Kern SE: Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol 1997;150:1547-1552.
18. Gaidano G, Ballerini P, Gong JZ, et al.: p53 mutations in human lymphoid malignancies: Association with burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88: 5413-5417.
19. Buetow KH, Sheffield VC, Zhu M, et al.: Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA 1992;89:9622-9626.
20. Duraisamy G, Zuridah H, Ariffin MY: Prevalence of hepatitis C virus antibodies in blood donors in Malaysia. Med J Malaysia 1993;48:313-316.
21. Yuan JM, Govindarajan S, Henderson BE, et al.: Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br J Cancer 1996;74: 491-493.
22. Okuno H, Xie ZC, Lu BY, et al.: A low prevalence of anti-hepatitis C virus antibody in patients with hepatocellular carcinoma in Guangxi Province, southern China. Cancer 1994;73:58-62.
23. Shackel NA, McGuinness PH, Abbott CA, et al.: Insights into the pathobiology of hepatitis C virus-associated cirrhosis: Analysis of intrahepatic differential gene expression. Am J Pathol 2002;160: 641-654.
24. Ihara A, Koizumi H, Hashizume R, et al.: Expression of epithelial cadherin and α- and β-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996;23:1441-1447.
25. Wong CM, Fan ST, Ng IO: β-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 2001;92:136-145.
26. Rimm DL, Caca K, Hu G, et al.: Frequent nuclear/cytoplasmic localizafion of β-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999;154:325-329.
27. Palacios J, Gamallo C: Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-1347.
28. Fukuchi T, Sakamoto M, Tsuda H, et al.: β-Catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58: 3526-3528.
29. Cagatay T, Ozturk M: p53 mutation as a source of aberrant β-catenin accumulation in cancer cells. Oncogene 2002;21:7971-7980.
30. Stern MC, Umbach DM, Yu MC, et al.: Hepatitis B, aflatoxin B1, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001;10: 617-625.
31. Hussain SP, Harris CC: Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-4037.
32. Wild CP, Jansen LA, Cova L, et al.: Molecular dosimetry of aflatoxin exposure: Contribution to understanding the multi-factorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect 1993;99:115-122.
33. Ross RK, Yuan JM, Yu MC, et al.: Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-946.
34. Qian GS, Ross RK, Yu MC, et al.: Follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3-10.